? 關(guān)鍵詞 阿替利珠單抗 貝伐珠單抗 帕博利珠單抗 曲妥珠單抗 西米普利單抗?派姆單抗 索米妥昔單抗 德曲妥珠單抗 恩諾單抗 英夫利昔單抗 ?

#今日行業(yè)熱點(diǎn)#

①The Lancet：Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial 臨床試驗(yàn)：阿替利珠單抗（Atezolizumab）聯(lián)合貝伐珠單抗（Bevacizumab）與主動(dòng)監(jiān)測(cè)在高危肝細(xì)胞癌患者中的比較(IMbrave050):一項(xiàng)隨機(jī)、開放標(biāo)簽、多中心、Ⅲ期試驗(yàn) DOI: 10.1016/S0140-6736(23)01796-8 ②The Lancet：Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial 臨床分析：帕博利珠單抗（Pembrolizumab）聯(lián)合曲妥珠單抗（Trastuzumab）和化療用于HER2陽(yáng)性胃癌或食管胃結(jié)合部腺癌的隨機(jī)Ⅲ期KEYNOTE-811研究 DOI: 10.1016/S0140-6736(23)02033-0 ③The Lancet：Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial 臨床跟蹤：可降解聚合物西羅莫司洗脫支架與耐用聚合物依維莫司洗脫支架用于ST段抬高型心肌梗死（STEMI）的長(zhǎng)期結(jié)局比較:BIOSTEMI隨機(jī)優(yōu)效性試驗(yàn)的5年隨訪 DOI: 10.1016/S0140-6736(23)02197-9 ④The Lancet Oncology：Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study 臨床數(shù)據(jù)：抗PD-1抑制劑西米普利單抗（cemiplimab）新輔助治療用于II-IV 期可切除的皮膚鱗狀細(xì)胞癌的單臂、多中心、Ⅱ期研究的隨訪和生存結(jié)果 DOI: 10.1016/S1470-2045(23)00459-X ⑤The Lancet Oncology：Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial 臨床數(shù)據(jù)：帕博利珠單抗（Pembrolizumab）聯(lián)合化療對(duì)比安慰劑聯(lián)合化療用于HER2陰性晚期胃癌(KEYNOTE-859):一項(xiàng)多中心、隨機(jī)、雙盲、Ⅲ期試驗(yàn) DOI: 10.1016/S1470-2045(23)00515-6 ⑥The Lancet Haematology：Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT 綜述：異基因造血干細(xì)胞移植用于骨髓增生異常綜合征的種系易感性特征 DOI: 10.1016/S2352-3026(23)00265-X ⑦針對(duì)葉酸受體α（FRα）靶點(diǎn)的ADC藥物索米妥昔單抗（Mirvetuximab Soravtansine Injection）用于葉酸受體α（FRα）陽(yáng)性的鉑類耐藥的上皮性卵巢癌、輸卵管癌或原發(fā)性腹膜癌的上市許可申請(qǐng)獲受理 ⑧抗體偶聯(lián)藥物德曲妥珠單抗（Trastuzumab Deruxtecan）在HER2表達(dá)的實(shí)體瘤的II期臨床試驗(yàn)DESTINY-PanTumor02 中顯示出對(duì)多種HER2表達(dá)晚期實(shí)體瘤患者具有臨床意義的生存獲益 ⑨恩諾單抗（enfortumab vedotin）聯(lián)合帕博利珠單抗（Pembrolizumab）用于局部晚期或轉(zhuǎn)移性尿路上皮癌的EV-302臨床研究達(dá)到了總生存期和無進(jìn)展生存期的雙重主要終點(diǎn) ⑩TNFα單抗生物類似藥皮下制劑英夫利昔單抗（Infliximab）獲FDA批準(zhǔn)上市，用于中重度活動(dòng)性潰瘍性結(jié)腸炎（UC）和克羅恩?。–D） 科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！